• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.

作者信息

Martins-Branco Diogo, Nader-Marta Guilherme, Molinelli Chiara, Ameye Lieveke, de Azambuja Evandro

机构信息

Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Rue Meylemeersch 90, 1070 Bruxelles, Belgium.

Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Rue Meylemeersch 90, 1070 Bruxelles, Belgium.

出版信息

Eur J Cancer. 2024 Sep;208:114195. doi: 10.1016/j.ejca.2024.114195. Epub 2024 Jul 2.

DOI:10.1016/j.ejca.2024.114195
PMID:38996796
Abstract
摘要

相似文献

1
Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.对关于“新辅助内分泌治疗后Ki-67指数作为雌激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌患者的预后生物标志物：一项系统评价和荟萃分析”信件的回复
Eur J Cancer. 2024 Sep;208:114195. doi: 10.1016/j.ejca.2024.114195. Epub 2024 Jul 2.
2
Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A systematic review and meta-analysis.
Eur J Cancer. 2024 Aug;207:114126. doi: 10.1016/j.ejca.2024.114126. Epub 2024 May 22.
3
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.中心评估的雌激素受体（ER）、孕激素受体（PgR）和Ki-67对激素受体阳性、人表皮生长因子受体2（HER2）阴性的绝经前早期乳腺癌患者选择辅助内分泌治疗的预测价值及临床应用：TEXT和SOFT试验
Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z. Epub 2015 Oct 22.
4
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.绝经后激素受体阳性、HER2 阴性乳腺癌患者接受芳香化酶抑制剂新辅助内分泌治疗后，孕激素受体与术前内分泌预后指数（PEPI）联合作为预后因素的影响。
PLoS One. 2018 Aug 6;13(8):e0201846. doi: 10.1371/journal.pone.0201846. eCollection 2018.
5
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.短期术前他莫昔芬治疗后 ER 阳性乳腺癌患者 Ki-67 标记指数的预后意义。
Ann Oncol. 2011 Mar;22(3):582-587. doi: 10.1093/annonc/mdq427. Epub 2010 Aug 17.
6
Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer.鉴定早期乳腺癌中预测新辅助内分泌治疗反应的基因表达
Breast Cancer Res Treat. 2025 Jun;211(3):717-725. doi: 10.1007/s10549-025-07693-8. Epub 2025 Apr 9.
7
Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.在接受新辅助化疗的局部晚期乳腺癌患者中，核心活检和明确组织学标本中 ER、PgR、HER-2 和 Ki-67 的表达。
Cancer Chemother Pharmacol. 2020 Jan;85(1):105-111. doi: 10.1007/s00280-019-03981-5. Epub 2019 Nov 21.
8
Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.保乳手术后最大直径小于或等于 2cm 的乳腺癌免疫组化定义亚型的长期预后
J Surg Res. 2019 Apr;236:288-299. doi: 10.1016/j.jss.2018.11.028. Epub 2018 Dec 27.
9
A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.基于新辅助化疗后雌激素受体表达和 Ki-67 值相结合的预后模型预测局部晚期乳腺癌的临床结局：对先前报道的患者队列的扩展和分析。
Eur J Surg Oncol. 2013 Oct;39(10):1046-52. doi: 10.1016/j.ejso.2013.06.024. Epub 2013 Jul 26.
10
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.免疫组织化学在接受新辅助化疗的乳腺癌患者中的作用：一种具有持久预后价值的古老工具。
Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.